Avelumab
Monoclonal antibody
Evidence outlook
Approved: Merkel Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (2)
- Treatment of unresectable Merkel cell carcinoma
- Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first?line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum?based chemotherapy.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02155647 NCT02155647 · Merkel Cell Carcinoma Registry: NCT02155647 | 2 | Part A: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 (Up to 113 weeks); Part B: Durable Response Rate (DRR) (Up to 161 weeks) 2019-05-02 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (120)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (64)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (52)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (2)
What this study did
What this study did
Competitive landscape
Other PD-L1 drugs
Atezolizumab, Durvalumab, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), Adebrelimab, Envafolimab and 7 more. Compare all 13 PD-L1 drugs
This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Merkel Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Avelumab: this drug | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved(overall) | Monoclonal antibody | PD-L1 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Weak signal | NCT03783078: Objective Response Rate (ORR) (Up to ~34 months): Pembrolizumab 200 mg 49.1 Percentage of participants (95% CI 35.4 to 62.9) NCT02267603: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Up to 3 years): Treatment (Pembrolizumab) — Number participants with partial response (PR): 16 Participants; Number participants with complete response (CR): 12 Participants; Combined total participants with either PR or CR: 28 Participants | |
| Retifanlimab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved(overall) | Monoclonal antibody | PD-L1 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Adebrelimab | Phase 3(overall) | Monoclonal antibody | PD-L1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Envafolimab | Phase 3(overall) | Monoclonal antibody | PD-L1 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Fetrastobart Vedotin | Phase 3(overall) | Antibody–drug conjugate | PD-L1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Sugemalimab (Cejemly) | Phase 3(overall) | Monoclonal antibody | PD-L1 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Tagitanlimab | Phase 3(overall) | Monoclonal antibody | PD-L1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HLX43 | Phase 2/3(overall) | Antibody–drug conjugate | PD-L1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| IFx-2.0 | Phase 2/3 | Gene therapy / editing | Innate immune activation (intralesional plasmid DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| 177Lu-RAD204 | Phase 1(overall) | Radiopharmaceutical | PD-L1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BPI-371153 | Phase 1(overall) | Small molecule | PD-L1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| IBC-Ab002 | Phase 1(overall) | Monoclonal antibody | PD-L1 | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(35 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Avelumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.